Bromide

Bromide

SCHEMBL19664892

Fc1ccc(-c2nc3c[n+](Cc4ccccc4)ccc3o2)cc1F.[Br-]

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.42
ESR1 P03372 2/20 0.39
ESR2 Q92731 2/20 0.39
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
PTPN5 P54829 1/20 0.39
HPSE Q9Y251 6/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
CASP3 P42574 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
TP53 P04637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20250842 0.99 HDAC6 (0.43) HDAC6ESR1ESR2PTPN2PTPN1
SCHEMBL3666752 0.77 F2 (0.49) PTPN2PTPN1PTPN5SMN1; SMN2KDM4E
SCHEMBL699617 0.74 NPC1 (0.58) HDAC6ESR1ESR2PTPN2PTPN1
Hydrochloric Acid SCHEMBL11545204 0.71 ALDH1A1 (0.55) SMN1; SMN2TP53KDM4ENPC1ALDH1A1
SCHEMBL17984874 0.66 HDAC6 (0.52) HDAC6ESR1ESR2SMN1; SMN2TP53
Bromide SCHEMBL19664819 0.64 MGLL (0.42) HDAC6KDM4ENPC1ALDH1A1
SCHEMBL11697224 0.63 NPC1 (0.59) ESR1ESR2PTPN2PTPN1PTPN5
SCHEMBL12997099 0.63 NPC1 (0.62) ESR1ESR2PTPN2PTPN1PTPN5
SCHEMBL16215311 0.63 NPC1 (0.64) HDAC6ESR1ESR2SMN1; SMN2CASP3
SCHEMBL11696502 0.63 NPC1 (0.50) ESR1ESR2PTPN2PTPN1PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
EP-3252059-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE Medshine Discovery Inc. (CN) 2017-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE NDUFV1, NDUFV2, MT-ND4 HDAC6 203/4885ESR1 4541/4885ESR2 3511/4885
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative NDUFV1, NDUFV2, MT-ND4 HDAC6 203/4885ESR1 4541/4885ESR2 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.